<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Brotizolam and Related Thienotriazolodiazepines for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Primary Use</td>
</tr>
<tr>
<td class="label">Brotizolam</td>
<td>Insomnia, anxiety</td>
</tr>
<tr>
<td class="label">Etizolam</td>
<td>Anxiety, insomnia</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>Seizures, RBD</td>
</tr>
<tr>
<td class="label">Flunitrazepam</td>
<td>Insomnia</td>
</tr>
<tr>
<td class="label">Temazepam</td>
<td>Insomnia</td>
</tr>
<tr>
<td class="label">Lorazepam</td>
<td>Anxiety, insomnia</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Dose Range</td>
</tr>
<tr>
<td class="label">Brotizolam</td>
<td>0.125-0.25 mg HS</td>
</tr>
<tr>
<td class="label">Etizolam</td>
<td>0.25-0.5 mg HS/TID</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>0.25-2.0 mg HS</td>
</tr>
<tr>
<td class="label">Flunitrazepam</td>
<td>0.5-2.0 mg HS</td>
</tr>
<tr>
<td class="label">Temazepam</td>
<td>7.5-30 mg HS</td>
</tr>
<tr>
<td class="label">Lorazepam</td>
<td>0.5-2.0 mg HS</td>
</tr>
</table>
Brotizolam and related thienotriazolodiazepines represent a class of benzodiazepine derivatives that have been investigated for potential neuroprotective effects in neurodegenerative diseases. These compounds primarily act on GABA-A receptors but may have additional effects relevant to neurodegeneration, particularly in the context of REM sleep behavior disorder (RBD), which is a common prodromal feature of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)[@schenck2007][@iranzo2006]. The thienotriazolodiazepine class includes brotizolam, etizolam, and related compounds that have been used clinically for anxiety and insomnia, and have shown potential effects in neurodegenerative disease models.
The recognition that REM sleep behavior disorder often precedes the development of classic neurodegenerative syndromes by years or decades has generated interest in understanding how sleep modifications relate to disease pathogenesis and whether early intervention might modify disease progression["@postuma2015"]. Benzodiazepines, particularly clonazepam, have been the cornerstone of RBD management for decades, but the thienotriazolodiazepines offer potential advantages including different receptor binding profiles and possibly enhanced neuroprotective properties["@stavropoulos2023"].
The primary mechanism of action for thienotriazolodiazepines involves modulation of the GABA-A receptor complex, the major inhibitory neurotransmitter receptor in the central nervous system. These compounds bind to the benzodiazepine site on the GABA-A receptor, enhancing the effect of gamma-aminobutyric acid (GABA) on neuronal excitability. This enhancement leads to increased chloride ion influx through the receptor channel, hyperpolarizing the postsynaptic neuron and reducing firing rates.
The GABAergic system plays a critical role in neurodegenerative diseases, and dysfunction of GABAergic signaling contributes to the motor and non-motor symptoms of Parkinson's disease and related disorders[@ibrahim2021]. In RBD, the normal muscle atonia that characterizes REM sleep is lost due to dysfunction in the brainstem circuits that control REM sleep muscle paralysis. Benzodiazepines may ameliorate RBD symptoms by enhancing GABAergic inhibition in these brainstem circuits, although the exact mechanism remains incompletely understood.
Several studies suggest that benzodiazepine derivatives may increase the expression of brain-derived neurotrophic factor (BDNF) and other neuroprotective growth factors[@bhattacharjee2021]. BDNF is a critical neurotrophin that supports the survival and function of dopaminergic neurons, which are progressively lost in Parkinson's disease. The potential to increase BDNF expression represents a disease-modifying mechanism that could potentially slow neurodegeneration, although this effect has not been definitively demonstrated in clinical settings.
Thienotriazolodiazepines may reduce calcium influx through voltage-gated calcium channels, which could protect neurons against excitotoxic damage. Excessive calcium influx through voltage-gated channels can trigger apoptotic pathways and contribute to neuronal death in neurodegenerative conditions. The calcium channel modulating effects of these compounds are less well-characterized than their GABAergic actions but may contribute to their potential neuroprotective properties.
Suppression of microglial activation and cytokine production has been reported for some benzodiazepine derivatives. Neuroinflammation is increasingly recognized as a key contributor to neurodegeneration in Parkinson's disease and related disorders, with activated microglia producing pro-inflammatory cytokines that damage neurons. The anti-inflammatory effects of thienotriazolodiazepines may therefore contribute to neuroprotection beyond their direct effects on neuronal function.
Preservation of mitochondrial function under stress conditions has been reported in preclinical studies of certain benzodiazepine derivatives. Mitochondrial dysfunction is a central feature of Parkinson's disease pathogenesis, with Complex I deficiency being a well-documented finding in PD patient tissue. Compounds that protect mitochondrial function could potentially slow disease progression by maintaining cellular energy metabolism and reducing oxidative stress.
Benzodiazepines are frequently used in Parkinson's disease for management of RBD and sleep disturbances:
DLB is characterized by prominent RBD, which often precedes the development of cognitive symptoms:
MSA is a progressive synucleinopathy characterized by autonomic failure, parkinsonism, and cerebellar ataxia:
Idiopathic RBD is now recognized as a prodromal synucleinopathy:
Dosing considerations:
Whether benzodiazepine treatment in the prodromal RBD period can modify the eventual development of clinically manifest neurodegenerative disease is unknown. The long prodromal period in synucleinopathies provides a window for potential intervention, but the putative neuroprotective mechanisms of these compounds need to be demonstrated in clinical studies.
The preclinical data suggesting neurotrophin expression, mitochondrial protection, and anti-inflammatory effects need to be translated to clinical studies. If these effects are clinically relevant, benzodiazepines could have disease-modifying benefits beyond their symptom management in RBD.
Identifying predictors of treatment response could help select patients most likely to benefit from benzodiazepine therapy. Polysomnographic features, genetic polymorphisms in GABAergic receptors, and disease-specific biomarkers may predict response.
Developing benzodiazepine derivatives with improved safety profiles, particularly reduced fall risk and cognitive effects, would be valuable. The thienotriazolodiazepine class may have some advantages, but head-to-head comparisons are lacking.
The relationship between RBD and synucleinopathies reflects the underlying pathology of these disorders. In Parkinson's disease, the pathological process begins in the brainstem and spreads upward to involve the substantia nigra and eventually the cortex[@braak2003]. The brainstem nuclei that control REM sleep atonia are affected early in this process, leading to RBD that often precedes motor symptoms by years or decades.
The alpha-synuclein pathology that characterizes PD, DLB, and MSA affects multiple brain regions and leads to the diverse clinical manifestations of these disorders. The presence of RBD indicates more widespread pathology and is associated with more rapid disease progression and higher risk of developing non-motor complications including cognitive impairment and autonomic dysfunction[@aarsland2021].
The bidirectional relationship between sleep and neurodegeneration is increasingly recognized. Sleep disturbances are not merely symptoms of neurodegeneration but may actively contribute to disease progression. Poor sleep increases oxidative stress and neuroinflammation, while neurodegeneration in turn disrupts sleep-wake cycles and circadian rhythms[@saper2010]. This vicious cycle makes sleep a potentially modifiable risk factor for disease progression.
aarsland2021, Dementia in Parkinson's disease (2021)
bhattacharjee2021, Benzodiazepines in neurodegenerative disorders: benefits and risks (2021)
braak2003, Staging of brain pathology related to sporadic Parkinson's disease (2003)
chen2022, Melatonin and clonazepam for REM sleep behavior disorder: a comparative study (2022)
ferreira2020, Pathophysiology of REM sleep behavior disorder in Parkinson's disease (2020)
gagnon2006, REM sleep behavior disorder in Parkinson's disease (2006)
ibrahim2021, GABAergic dysfunction in neurodegenerative disease (2021)
iranzo2006, Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder (2006)
jellinger2009, Formation and progression of alpha-synuclein pathology (2009)
jun2019, Etizolam in Parkinson's disease with REM sleep behavior disorder (2019)
kalia2015, Parkinson's disease (2015)
litvan2012, Movement disorders research: 25 years of progress (2012)
mcgurin2021, Dementia with Lewy bodies: update on treatment (2021)
montplaisir2005, Polysomnographic features of REM sleep behavior disorder (2005)
olson2020, Management of REM sleep behavior disorder: an evidence-based review (2020)
postuma2015, Idiopathic REM sleep behavior disorder: a longitudinal study (2015)
saper2010, Sleep state switching (2010)
schenck2007, Clonazepam treatment of REM sleep behavior disorder: a retrospective review (2007)
sixel2011, Sleep and neurodegeneration (2011)
spillantini2000, Alpha-synucleinopathies: a new approach to disease classification (2000)
stavropoulos2023, Thienotriazolodiazepines in neurodegenerative disease (2023)
wolters2008, The dopamine hypothesis of Parkinson's disease (2008)
wulff2010, The role of benzodiazepines in the treatment of sleep disorders (2010)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: